ACROSTUDY: Pegvisomant safe, effective for long-term use in acromegaly

Real-world data from the long-term ACROSTUDY show the growth hormone receptor agonist pegvisomant is safe and effective, with a low incidence of liver enzyme elevation and no increase in tumor size for most patients with acromegaly. In a comprehensive review of the ACROSTUDY, initiated in 2004 to investigate the long-term effects of pegvisomant (Somavert, Pfizer) in a real-world, international

Read the full article here

Related Articles